[go: up one dir, main page]

MX2009004170A - Materiales y metodos para inmunoglicoproteinas mejoradas. - Google Patents

Materiales y metodos para inmunoglicoproteinas mejoradas.

Info

Publication number
MX2009004170A
MX2009004170A MX2009004170A MX2009004170A MX2009004170A MX 2009004170 A MX2009004170 A MX 2009004170A MX 2009004170 A MX2009004170 A MX 2009004170A MX 2009004170 A MX2009004170 A MX 2009004170A MX 2009004170 A MX2009004170 A MX 2009004170A
Authority
MX
Mexico
Prior art keywords
castanospermine
dependent cytotoxicity
increasing antibody
immunoglycoproteins
antibody
Prior art date
Application number
MX2009004170A
Other languages
English (en)
Inventor
Baum Peter Robert
Thompson Peter Armstrong
Espling Erik Stephen
Original Assignee
Trubion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trubion Pharmaceuticals Inc filed Critical Trubion Pharmaceuticals Inc
Publication of MX2009004170A publication Critical patent/MX2009004170A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Las inmunoglicoproteínas incluyen anticuerpos, con una ADCC (citotoxicidad dependiente de anticuerpos) mejorada y se proveen patrones de glicosilación alterados. También se proporcionan métodos de cultivo celular y los medios para producir tales inmunoglicoproteínas y usos terapéuticos de tales inmunoglicoproteínas.
MX2009004170A 2006-10-24 2007-10-24 Materiales y metodos para inmunoglicoproteinas mejoradas. MX2009004170A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85394406P 2006-10-24 2006-10-24
PCT/US2007/082343 WO2008052030A2 (en) 2006-10-24 2007-10-24 A method for increasing antibody-dependent cytotoxicity with castanospermine

Publications (1)

Publication Number Publication Date
MX2009004170A true MX2009004170A (es) 2009-06-26

Family

ID=39204867

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004170A MX2009004170A (es) 2006-10-24 2007-10-24 Materiales y metodos para inmunoglicoproteinas mejoradas.

Country Status (9)

Country Link
US (2) US20100150948A1 (es)
EP (1) EP2076538A2 (es)
JP (1) JP2010507394A (es)
CN (1) CN101646688A (es)
AU (1) AU2007308983B2 (es)
BR (1) BRPI0717601A2 (es)
CA (1) CA2663536A1 (es)
MX (1) MX2009004170A (es)
WO (1) WO2008052030A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
HUE026303T2 (hu) 2005-07-25 2016-06-28 Emergent Product Dev Seattle B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
US7846434B2 (en) * 2006-10-24 2010-12-07 Trubion Pharmaceuticals, Inc. Materials and methods for improved immunoglycoproteins
AU2009234277B2 (en) 2008-04-11 2014-12-04 Aptevo Research And Development Llc CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
CN102076865B (zh) 2008-05-02 2016-03-16 西雅图基因公司 用于制造核心岩藻糖基化降低的抗体和抗体衍生物的方法和组合物
HRP20180045T1 (hr) 2008-10-02 2018-03-23 Aptevo Research And Development Llc Proteini antagonisti cd86 koji se vežu na više meta
CA2767225A1 (en) * 2009-07-06 2011-01-13 Alnylam Pharmaceuticals, Inc. Compositions and methods for enhancing production of a biological product
WO2011079308A2 (en) 2009-12-23 2011-06-30 Emergent Product Development Seattle, Llc Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
EP2519544A1 (en) 2009-12-29 2012-11-07 Emergent Product Development Seattle, LLC Polypeptide heterodimers and uses thereof
SG10201501803YA (en) 2010-03-12 2015-05-28 Immunogen Inc Cd37-binding molecules and immunoconjugates thereof
WO2012019165A2 (en) 2010-08-05 2012-02-09 Seattle Genetics, Inc. Methods of inhibition of protein fucosylation in vivo using fucose analogs
EP2694105A4 (en) 2011-04-01 2015-04-29 Immunogen Inc CD37 BINDING MOLECULES AND IMMUNOCONJUGATES THEREOF
CA2882725C (en) 2012-08-23 2021-03-09 Regents Of The University Of Minnesota Treatment of sickle cell disease and inflammatory conditions
HUE071397T2 (hu) * 2013-10-31 2025-08-28 Amgen Inc Monenzin alkalmazása rekombináns fehérjék glikozilációjának szabályozására
JP6979877B2 (ja) 2015-06-08 2021-12-15 デビオファーム インターナショナル， エス． アー． 抗ｃｄ３７イムノコンジュゲートおよび抗ｃｄ２０抗体の組み合わせ
CA2995243A1 (en) 2015-08-28 2017-03-09 Debiopharm International, S.A. Antibodies and assays for detection of cd37
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
JP2020510608A (ja) 2016-11-02 2020-04-09 デビオファーム インターナショナル， エス． アー． 抗ｃｄ３７イムノコンジュゲート療法を改善するための方法
KR102584340B1 (ko) 2016-11-03 2023-10-10 브리스톨-마이어스 스큅 컴퍼니 활성화가능한 항-ctla-4 항체 및 그의 용도
SG11202009216YA (en) 2018-03-26 2020-10-29 Amgen Inc Total afucosylated glycoforms of antibodies produced in cell culture
JP2021525735A (ja) 2018-05-30 2021-09-27 デビオファーム インターナショナル， エス． アー． 抗ｃｄ３７免疫コンジュゲート投薬レジメン
JP2022514299A (ja) * 2018-12-19 2022-02-10 シージェン インコーポレイテッド 抗体の制御されたフコシル化
WO2025245176A1 (en) 2024-05-22 2025-11-27 Bristol-Myers Squibb Company Multispecific antibody constructs

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
WO1992016622A1 (en) * 1991-03-12 1992-10-01 Biogen, Inc. Cd2-binding domain of lymphocyte function associated antigen 3
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7560534B2 (en) * 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
DK1354034T3 (da) * 2000-11-30 2008-03-25 Medarex Inc Transgene transchromosomale gnavere til fremstilling af humane antistoffer
US6979556B2 (en) * 2000-12-14 2005-12-27 Genentech, Inc. Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
JP4213586B2 (ja) * 2001-09-13 2009-01-21 株式会社抗体研究所 ラクダ抗体ライブラリーの作製方法
ATE430580T1 (de) * 2001-10-25 2009-05-15 Genentech Inc Glycoprotein-zusammensetzungen
US20040038304A1 (en) * 2002-03-28 2004-02-26 Gala Design, Inc. Antibody libraries
MXPA04009418A (es) * 2002-03-29 2005-06-08 Schering Corp Anticuerpos monoclonales humanos par interleucina-5, y metodos y composiciones que comprenden los mismos.
WO2005081687A2 (en) * 2003-09-30 2005-09-09 Centocor, Inc. Human hinge core mimetibodies, compositions, methods and uses
JP2007510416A (ja) * 2003-11-03 2007-04-26 セントカー・インコーポレーテツド バイオプロセッシングシステムにおいて低剪断を維持する方法
HUE026303T2 (hu) * 2005-07-25 2016-06-28 Emergent Product Dev Seattle B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával
DK1945665T3 (da) * 2005-10-21 2012-02-06 Genzyme Corp Antistof-baserede terapimidler med forhøjet ADCC-aktivitet

Also Published As

Publication number Publication date
WO2008052030A3 (en) 2008-06-12
JP2010507394A (ja) 2010-03-11
AU2007308983B2 (en) 2012-12-06
CA2663536A1 (en) 2008-05-02
CN101646688A (zh) 2010-02-10
AU2007308983A1 (en) 2008-05-02
US20100150948A1 (en) 2010-06-17
BRPI0717601A2 (pt) 2013-10-22
EP2076538A2 (en) 2009-07-08
US20130280240A1 (en) 2013-10-24
WO2008052030A2 (en) 2008-05-02

Similar Documents

Publication Publication Date Title
MX2009004170A (es) Materiales y metodos para inmunoglicoproteinas mejoradas.
WO2009126858A3 (en) Materials and methods for improved immunoglycoproteins
EP2007386A4 (en) CAMPTOTHECIN ANALOGUE HAVING A NEW LACTONE STABLE RETURNED "RETURNED" CORE AND METHODS FOR PREPARING AND USING SAME
MX2007008506A (es) Metodos y productos para genotipificacion in vitro.
EP2225613A4 (en) METHOD FOR MANUFACTURING ELECTROPHOTOGRAPHIC CARRIER AND ELECTROPHOTOGRAPHIC CARRIER OBTAINED USING THE METHOD
MX300732B (es) Celulasas, acidos nucleicos que las codifican y metodos para hacerlas y usarlas.
EP2094844A4 (en) IMPROVED BUTANOL PRODUCING MICROORGANISMS AND METHOD FOR THE PRODUCTION OF BUTANOL THEREWITH
IL180125A0 (en) Methods for producing biodiesel
MX265618B (es) Metodo para preparar n-fenilpirazol-1-carboxamidas.
IL197459A0 (en) Humanized proteins, including antibodies and methods for producing the same
EP2092055A4 (en) NEW PREPARATION OF YEAST OF VITAMIN D2, PROCESS FOR PRODUCTION THEREOF AND USE THEREOF
EP2187177A4 (en) REFLECTOR PLATE FOR AN OPTICAL CODING DEVICE, METHOD FOR THE PRODUCTION THEREOF, AND OPTICAL CODING DEVICE
AP2290A (en) Method of producing a booklet, data page produced by this method and booklet by the method.
TWI318298B (en) Method for manufacturing a conductive contacter holder, and the conductive contacter holder
EP2119518A4 (en) FINE SILVER POWDER
WO2007120334A3 (en) Methods and compositions for targeting polyubiquitin
EP1911538A4 (en) EDGE REPLACEMENT CUTTING HEAD AND METHOD FOR PRODUCING THE SAME
EP2014824B8 (en) Reinforcing cord, method for producing the same, and product using the reinforcing cord
WO2008086228A3 (en) Arrays and methods for guided cell patterning
MX280092B (es) Proceso para producir un compuesto de 5 - hidroxi - 4 - tiometilpirazol.
SG129313A1 (en) Carbon black, method for producing the same, and its use
PL1985176T3 (pl) Zabarwiona żyłka wędkarska i proces jej wytwarzania
WO2007014373A3 (en) Novel cells, compositions, and methods
IL179884A0 (en) Fuel cells, micro-fuel cells and methods for the production thereof
EP2186776A4 (en) ORGANIC CLAY COMPLEX, PROCESS FOR PRODUCING THE SAME AND RESIN COMPLEX CONTAINING ORGANIC CLAY COMPLEX

Legal Events

Date Code Title Description
FG Grant or registration